Spray nasal snoop 0.1 instruction. Snoop spray: instructions for use

1 ml of solution contains 0.5 (or 1.0) mg xylometazoline hydrochloride . Auxiliary components: potassium dihydrogen phosphate, sea ​​water, purified water.

Release form

A transparent solution is available in polyethylene bottles with a special spray valve. The volume of 15 ml is designed for 150 doses. Each pack of cardboard contains 1 bottle with the attached instructions from the manufacturer. Baby Snoop is available as a 0.05% colorless solution.

pharmachologic effect

The drug is used intranasally and has a pronounced vasoconstrictor effect . The active ingredient belongs to alpha-adrenomimetics, which have a stimulating effect on alpha-adrenergic receptors in the smooth muscle layer of the vascular wall. This mechanism of action provides a narrowing of the lumen of the vessels, a decrease in the severity of edema and hyperemia of the mucosa, a decrease. Snoop's nose drops let you in short time to stop the unpleasant symptoms of rhinitis various genesis. facilitates nasal breathing.

Pharmacodynamics and pharmacokinetics

Modern analytical methods do not allow to determine the total concentration of the active substance in the blood, because. the active ingredient is practically not absorbed into the systemic circulation when topical application. The therapeutic effect is registered within a few minutes after application and persists for several hours.

Indications for use

Spray Snoop is actively used in ENT practice to relieve negative symptoms with:

The drug can be prescribed before such a diagnostic manipulation as rhinoscopy , to facilitate the procedure, improve the patency of the nasal passages.

Contraindications

  • pronounced;
  • cardiopalmus;
  • a history of specialized surgical interventions on the meninges of the brain.

0.1% solution is not used in pediatric practice in children under 6 years old, 0.05% - up to 2 years.

Relative contraindications (use with caution):

  • angina pectoris (heart muscle).

Side effects

Nervous system:

  • sleep disorders;
  • violation of visual perception;
  • dizziness.

Respiratory system:

  • swelling of the nasal mucosa;
  • hypersecretion;
  • dryness of the mucosa;
  • irritation in the area of ​​application.

The cardiovascular system:

  • cardiopalmus;
  • climb ;
  • rhythm disturbances.

Vomiting and discomfort in the epigastric region are rarely observed. When registering other negative reactions, the help of a specialist is recommended, self-cancellation of the Spray Snoop medication.

Instructions for use (Method and dosage)

The medication is prescribed intranasally. Instructions for use Snoop: before the first use, it is necessary to press the sprayer several times to ensure correct dosing. The nasal spray can only be used after the nasal passages have been cleared of crusts and mucus. Nasal drops for adults at a concentration of 0.1% are sprayed three times a day in each nasal passage. The required time interval between sprays is 6 hours. The duration of treatment is 3-7 days. Long-term therapy can lead to atrophy of the mucosal wall, dose-dependence, and reduced efficacy. For children, a special solution with a concentration of 0.05% is produced. Children's Snoop is used 1 time per day, 1 spray in each nasal passage (relevant for children 2-6 years old).

Overdose

High doses may lead to serious violations in the work of the cardiac system (tachycardia,). Long term treatment high doses causes vomiting, paresthesia, dry mucous membranes, irritation of the walls of the nose, visual disturbances,. Chronic overdose is characterized by a depressive state. Specific

Snoop

Composition

1 g nasal spray Snoop 0.1% contains:
Xylometazoline hydrochloride - 1 mg;
Additional ingredients.

1 g nasal spray Snoop 0.05% contains:
Xylometazoline hydrochloride - 0.5 mg;
Additional ingredients.

pharmachologic effect

Snoop is a drug for intranasal use with a vasoconstrictor effect. Snoop contains xylometazoline hydrochloride, a substance of the alpha-adrenergic agonist group. Xylometazoline hydrochloride stimulates alpha-adrenergic receptors of the smooth muscle layer of the vessels of the nasal mucosa, resulting in vasoconstriction, a decrease in rhinorrhea, edema and hyperemia of the nasal mucosa and paranasal sinuses. Xylometazoline reduces the severity of symptoms of rhinitis of various etiologies, facilitates nasal breathing.
After a single application, the effect of the drug Snoop develops within 3-5 minutes and lasts up to 5 hours.
When applied topically, systemic absorption of xylometazoline is negligible.

Indications for use

Snoop is used for the symptomatic treatment of rhinitis in patients suffering from acute allergic rhinitis, sinusitis, hay fever and acute respiratory viral infections.
Snoop is also prescribed to patients suffering from eustachitis and otitis media.
Snoop can be recommended to reduce swelling and hyperemia of the nasal mucosa before rhinoscopy and other diagnostic procedures in the nasal passages.

Mode of application

Snoop is intended for intranasal use. Before the first use of the drug, it is recommended to press the sprayer several times to achieve the correct dosage of the spray. Before using the drug Snoop should clear the nasal passages of mucus. The dose of xylometazoline and the duration of therapy with Snoop is determined by the doctor.
Children 2 to 6 years of age are usually given 1 spray of Snoop 0.05% in each nasal passage.
Children over 6 years of age are usually prescribed xylometazoline at doses recommended for adults.

Maximum recommended daily dose Snoop 0.05% is 3 sprays in each nasal passage.
Adults are usually prescribed 1 spray of Snoop 0.1% in each nasal passage up to 3 times a day.
The minimum recommended interval between doses of Snoop is 6 hours. Do not apply the spray more than 3 times a day.
The recommended duration of therapy is 3 to 7 days.

Side effects

Snoop is generally well tolerated by patients. In some cases, when using xylometazoline, the development of dryness of the nasal mucosa was noted.
With frequent and prolonged use of xylometazoline, patients may develop paresthesia, sneezing, increased secretory activity of the glands of the nasal mucosa, tachycardia, headache, vomiting, arrhythmias, arterial hypertension, sleep disturbances, insomnia and decreased visual acuity. In addition, with prolonged use of xylometazoline, the development of depressive conditions is possible.

Contraindications

Snoop is not used to treat patients with individual hypersensitivity to xylometazoline or additional ingredients of the drug.
Snoop should not be used for long-term therapy, in particular, xylometazoline is not prescribed for patients with chronic rhinitis of various etiologies.
Snoop is not prescribed to patients suffering from arterial hypertension, severe atherosclerosis, cardiac arrhythmias, glaucoma, thyrotoxicosis and atrophic rhinitis.
Xylometazoline is not recommended for patients who have undergone meningeal surgery.
In pediatric practice, the drug Snoop 0.05% is used only for the treatment of children older than 2 years, Snoop 0.1% - for the treatment of children older than 6 years.

Pregnancy

The use of the drug Snoop is contraindicated during pregnancy.
During lactation, the use of xylometazoline is allowed only after the issue of temporary interruption has been resolved. breastfeeding.

drug interaction

The combined use of the drug Snoop with monoamine oxidase inhibitors and tricyclic antidepressants is prohibited.

Overdose

When using excessive doses of xylometazoline, patients may experience irritation and dryness of the nasal mucosa and oral cavity, as well as the development of paresthesia, tachycardia, arterial hypertension, vomiting, insomnia and visual impairment. With a chronic overdose of the drug Snoop, the development of depressive conditions is possible.
There is no specific antidote. With the development of symptoms of overdose, appropriate therapy is carried out. In case of an overdose of xylometazoline, the patient should be under medical supervision.

Release form

Nasal spray Snoop in polymer bottles with a sprayer of 15 ml (150 doses), in a cardboard box 1 bottle. Attention!
Description of the drug Snoop"on this page is a simplified and expanded version official instructions by application. Before purchasing or using the drug, you should consult your doctor and read the annotation approved by the manufacturer.
Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide on the appointment of the drug, as well as determine the dose and methods of its use.

Snoop is an effective drug, a decongestant for intranasal use, from the group of alpha-agonists, which has a pronounced vasoconstrictive effect. The active active ingredient of this medicinal product is xylometazoline hydrochloride. The mechanism of pharmaceutical action is based on the stimulation of alpha-adrenergic receptors of the smooth muscle layer of arterioles and venules of the nasal mucosa, resulting in narrowing of small vessels, a decrease in hyperemia and edema of the mucous membranes of the nasal passages and paranasal sinuses, and inhibition of mucus production. In this regard, the severity of symptoms of infectious or allergic rhinitis decreases and nasal breathing is facilitated.
This drug is available in the form of nasal drops and intranasal spray with a concentration of 0.05% and 0.1%.

snoop application

Indications for the use of Snoop are rhinitis of various etiologies (allergic or infectious), sinusitis, eustachitis, and also as part of combination therapy for acute otitis media, laryngopharyngitis, in the postoperative period and to prepare for diagnostic manipulations in the nasal cavity.

Contraindications to the use of Snoop

  • individual hypersensitivity to xylometazoline;
  • arterial hypertension;
  • severe atherosclerosis;
  • tachycardia;
  • angle-closure glaucoma;
  • pregnancy;
  • thyrotoxicosis;
  • craniocerebral trauma and / or surgical interventions (in history) on the meninges;
  • for 0.1% solution - children's age up to six years;
  • for a 0.05% solution, children's age up to two years;
  • when taking MAO inhibitors and antidepressants.

Snoop should be administered with caution:

  • during lactation;
  • with angina pectoris;
  • with prostatic hyperplasia;
  • with diabetes.

drops snoop

One of the forms of release of the drug Snup are intranasal drops with a solution concentration of 0.05% (used in children from two to six years old) and 0.1% (for adult patients, adolescents and children over six years of age).

Doses of the drug, the frequency and duration of its use is determined by the attending physician.

For adult patients, adolescents and children over twelve years of age, Snoop is prescribed in the form of a 0.1% solution, two to three drops from one to three times a day, locally intranasally. For children from seven to twelve years old, a 0.1% solution of the drug is used, Snoop is dosed one drop two to three times a day.

In young children (from two to seven years old), Snoop is prescribed in the form of a 0.05% solution and is applied one to two drops two to three times a day.

snoop spray

Snoop nasal spray is for topical use. It is important to remember that before the first use of the drug, in order to achieve the correct dosage of the aerosol, you need to press the sprayer several times.

In pediatric practice, Snoop nasal spray is prescribed at a solution concentration of 0.05% and is used from the age of two, one injection of the drug into each nasal passage after the child’s nasal passages have been previously cleared of mucus accumulated in them, the frequency of administration is no more than three times a day. The duration of therapy with Snoop is usually three to four days, but should not exceed seven days. The mucous membrane of the nasal passages and paranasal sinuses of a child is more tender and vulnerable than in adults, so prolonged exposure to vasoconstrictor drugs can cause irritation, dryness and burning. Uncontrolled use of decongestants for a long time can cause chronic edema and atrophic processes in the nasal mucosa and paranasal sinuses, aggravate chronic inflammatory processes and stimulate the growth of lymphoid tissue (adenoiditis and tonsillitis).
For children over six years of age, adolescents and adults, Snoop is prescribed in a 0.1% solution, topically, one spray every six hours (no more than three times a day).

snoop during pregnancy

The vasoconstrictor drug Snoop is contraindicated for use at any stage of pregnancy, due to the possible risk of developing side effects in pregnant women and adverse effects on the fetus.

Side effects when using the drug Snoop

With the frequent use of drugs containing xylometazoline, as an active active substance, patients may develop local reactions in the form of sneezing, dryness, burning, increased secretory activity of the glands and / or paresthesia of the nasal mucosa. As well as a violation of well-being with dizziness, tachycardia, headache, vomiting, arrhythmia, the development of arterial hypertension, insomnia and other sleep disorders, decreased visual acuity and the development of depressive states.

If any of these symptoms occur, you should immediately stop using the drug and seek medical help.

Xylometazoline does not have a specific antidote, therefore, patients with symptoms of an overdose or with the development side effects drug is carried out symptomatic therapy in a medical setting.

Parents need to know that intranasal drops and spray containing alpha-adrenergic agonist (xylometazoline or oxymetazoline) in their composition when taken orally (swallowing the drug) or used in a 0.1% solution often during the day, as well as with individual hypersensitivity, can cause symptoms of acute poisoning that threaten the life of the baby. Therefore, if swallowing is suspected or if symptoms of acute poisoning occur, sudden vomiting, severe weakness and drowsiness of the child or overexcitation, tachycardia, a sharp decrease blood pressure(fainting), respiratory disorders - urgent hospitalization of the child in a medical facility is necessary and emergency care– gastric lavage, detoxification and symptomatic treatment.

Late delivery medical care can cause respiratory arrest, cardiac arrest and coma (especially in children under three years of age).

snoop prices

The cost of nasal drops and spray Snoop is from 120 to 145 rubles, depending on the form of release.

snoop reviews

To date, the drug Snoop is an effective and mild vasoconstrictor, decongestant with alpha-adrenomimetic activity for intranasal use in pediatric, therapeutic and ENT practice. It eliminates swelling and hyperemia of the mucous membranes of the nasal cavity and paranasal sinuses, restoring the patency of the nasal passages, reduces rhinorrhea and facilitates the flow of mucus and nasal breathing. This drug is widely used to treat a runny nose with rhinitis of various etiologies (allergic or infectious), as part of a combination therapy for acute otitis media, laryngopharyngitis, sinusitis, eustachitis, as well as in the postoperative period and to prepare for diagnostic manipulations in the nasal cavity.

Release form

Composition

Spray for nasal use, composition (1 ml): active substance: xylometazoline hydrochloride - 1 mg; excipients: sea water - 250 mg; potassium dihydrogen phosphate - 0.45 mg; purified water - 753.85 mg theoretical total mass - 1005.3 mg

Pharmacological effect

vasoconstrictor, alpha-adrenomimetic

Pharmacokinetics

When applied topically, the drug is practically not absorbed, so its concentration in the blood plasma is very low (not determined by modern analytical methods).

Indications

acute respiratory diseases with symptoms of rhinitis (runny nose); acute allergic rhinitis, hay fever, sinusitis, eustachitis, otitis media(as part of combination therapy to reduce swelling of the nasopharyngeal mucosa); to facilitate rhinoscopy and other diagnostic procedures in the nasal passages.

Contraindications

hypersensitivity; arterial hypertension; tachycardia; severe atherosclerosis; glaucoma; atrophic rhinitis; thyrotoxicosis; surgical interventions on the meninges (in history); pregnancy; children's age up to 6 years (for 0.1% solution); children's age up to 2 years (for 0.05% solution). With caution: diabetes mellitus; heavy cardiovascular diseases(including coronary heart disease); prostatic hyperplasia; pheochromocytoma; porphyria; hyperthyroidism; breastfeeding period; simultaneous reception of MAO inhibitors; tricyclic antidepressants and others medicines that increase blood pressure; hypersensitivity to adrenergic drugs, accompanied by insomnia, dizziness, arrhythmia, tremor, increased blood pressure.

Dosage and administration

Intranasal. Snoop, nasal spray, 0.05%. Children aged 2 to 6 years - 1 injection in each nostril (can be repeated if necessary), up to 3 times a day. Adults and children over 6 years old - 2 injections in each nostril, up to 3 times a day. Snoop, spray for nasal use, 0.1%. Adults and children over 6 years old - 1 spray in each nostril (repeat if necessary), up to 3 times a day. Snoop, nasal spray, 0.1% should not be used in children under 6 years old. The drug should not be used more often 3 times a day, the duration of the course is no more than 7 days. Before use, it is necessary to clean the nasal passages. Remove the protective cap. Before the first use, press the rim of the spray nozzle several times (Fig. 1) until a uniform cloud of "fog" appears. The bottle with the drug is ready for further use. When using the nozzle, insert it into the nasal cavity and press once (Fig. 2) on the rim. Keep the bottle upright. Do not spray horizontally or downwards. Immediately after the injection, it is recommended to take a light breath through the nose. After use, close the vial with a protective cap. Each vial must be used individually.

Side effects

With frequent and / or prolonged use - irritation and / or dryness of the nasopharyngeal mucosa, burning, paresthesia, sneezing, hypersecretion. Rarely - swelling of the nasal mucosa, palpitations, tachycardia, arrhythmias, increased blood pressure, headache, vomiting, insomnia, blurred vision; depression (with prolonged use in high doses).

Overdose

Symptoms: increased side effects. Treatment: symptomatic, under medical supervision.

Interaction with other drugs

Incompatible with MAO inhibitors and tricyclic antidepressants.

special instructions

It should not be used for a long time, for example, in chronic rhinitis. Sea water, which is part of the drug, helps maintain the normal physiological state of the nasal mucosa due to the ability to improve the function ciliated epithelium and normalization of mucus production in the goblet cells of the mucous membrane. Influence on the ability to manage vehicles and mechanisms. Subject to the dosing regimen, xylometazoline does not affect the concentration of attention and the speed of psychomotor reactions.

1 ml nasal spray 0.05% contains:

active ingredient - xylometazoline hydrochloride - 0.50 mg;

other ingredients: sea ​​water - 250.0 mg, potassium dihydrogen phosphate - 0.45 mg, purified water - 754.35 mg.

1 ml nasal spray 0.1% contains:

active ingredient- xylometazoline hydrochloride - 1.0 mg;

other ingredients: sea ​​water - 250.0 mg, potassium dihydrogen phosphate - 0.45 mg, purified water - 753.85 mg.

Description

Colorless transparent solution.

Pharmacotherapeutic group

Decongestants and other topical nasal preparations. Sympathomimetics. ATX code: R01AA07.

Pharmacological properties

Pharmacodynamics

Xylometazoline belongs to the group of local vasoconstrictors with alpha-adrenomimetic activity, causes narrowing of the blood vessels of the nasal mucosa, eliminating swelling and hyperemia of the nasal mucosa, restores the patency of the nasal passages, facilitates nasal breathing.

The effect of the drug occurs within a few minutes after its application and lasts for several hours (average 6-8 hours).

Pharmacokinetics

When applied topically, the drug is practically not absorbed, so its concentration in the blood plasma is very low (not determined by modern analytical methods).

Indications for use

Acute respiratory diseases with rhinitis (runny nose), acute allergic rhinitis, hay fever, sinusitis, eustachitis, otitis media (as part of combination therapy to reduce swelling of the nasopharyngeal mucosa), to facilitate rhinoscopy and other diagnostic manipulations in the nasal passages.

Contraindications

Hypersensitivity to the components of the drug, angle-closure glaucoma, atrophic rhinitis, dry rhinitis, thyrotoxicosis, transsphenoidal hypophysectomy or other surgical interventions on the meninges (in history), children under 12 years of age (for a 0.1% solution), children under 2 years of age ( for 0.05% solution).

Dosage and administration

Before use, it is necessary to clean the nasal passages (blow your nose), remove the protective cap from the vial. Before the first use or after a long break in use, press the spray valve several times until a dispersed jet appears. When spraying into the nostril, the bottle should be in a vertical position, pressing the valve is done while inhaling. After use, it is recommended to clean the nozzle and close the vial with a protective cap.

Snoop® nasal spray 0.05%

Children aged 2 to 12 years: 1 spray in each nostril (may be repeated if necessary), up to three times a day.

Snoop® nasal spray 0.1%

Adults and children over 12 years: 1 spray in each nostril (repeat if necessary), up to three times a day.

The drug should not be used more than three times a day, the duration of the course of treatment is not more than 7 days.

Pobochaction

Criteria for the frequency of occurrence of adverse reactions: very often (≥ 1/10), often (≥ 1/100,

Heart disorders: infrequently - palpitations, tachycardia; very rarely - arrhythmia.

Violations by nervous system: very rarely - headache, convulsions (especially in children).

Violations by respiratory system, bodies chest and mediastinum: often - burning and dryness of the nasal mucosa, sneezing; infrequently - swelling of the mucous membrane of the nasal cavity, nosebleeds; very rarely - apnea (noted in young children and newborns).

Vascular disorders: infrequently - arterial hypertension.

General disorders: increased fatigue (drowsiness, sedation).

Violations by immune system: infrequently - hypersensitivity reactions (angioneurotic edema, skin rash, itching).

Mental disorders: very rarely - anxiety, insomnia, hallucinations (mainly in children).

In the event of adverse reactions, including those not listed in this leaflet, you should stop using the drug and consult a doctor.

Overdose

Symptoms of stimulation of the central nervous system are anxiety (feeling of fear, anxiety), agitation, hallucinations, convulsions. Symptoms of depression of the central nervous system are a decrease in body temperature, lethargy, drowsiness, coma.

The following additional symptoms may occur: miosis, mydriasis, sweating, fever, pallor, cyanosis, nausea, vomiting, tachycardia, bradycardia, cardiac arrhythmia, cardiac arrest, arterial hypertension or hypotension, pulmonary edema, respiratory failure and apnea.

Overdose (especially in children) often leads to the following effects of the central nervous system: convulsions, coma, bradycardia, apnea, arterial hypertension, which may be replaced by arterial hypotension.

Treatment: there is no specific antidote. Treatment is symptomatic, under medical supervision. Vasoconstrictors are contraindicated. In severe overdose - intensive care in a hospital.

Precautionary measures

The drug should be used with caution in patients with severe cardiovascular disease (including ischemic disease hearts, arterial hypertension), hyperthyroidism, diabetes, pheochromocytoma, prostatic hyperplasia, porphyria, hypersensitivity to adrenergic drugs, accompanied by insomnia, dizziness, tremor, cardiac arrhythmias, increased blood pressure while taking monoamine oxidase inhibitors (MAOIs) and other drugs that increase blood pressure.

Do not use for more than 7 days in a row and do not exceed the recommended doses, especially at children and elderly patients: prolonged and excessive use of vasoconstrictors can lead to the development of drug-induced rhinitis, manifested by increased secretion of mucus and swelling of the nasal mucosa.

Use in children

Snoop® nasal spray 0.05% is contraindicated for use in childhood up to 2 years; used in children from 2 to 12 years.

Snoop® nasal spray 0.1% is contraindicated for use in children under 12 years of age; used in children over 12 years of age.

The use of the drug in children should be carried out under the supervision of adults. Recommended daily doses of the drug and the duration of the course of treatment are determined by the attending physician.

Use during pregnancy or lactation

Due to the vasoconstrictive properties of the drug, as a precaution, it should not be used during pregnancy.

It has not been established whether xylometazoline penetrates into breast milk when applied topically. The use of the drug during breastfeeding is possible only on the advice of a doctor, if the expected benefit to the mother outweighs the potential risk to the child.

Influence on the ability to drive vehicles and mechanisms

When used in recommended doses, the drug does not affect driving, working with mechanisms and performing potentially hazardous activities that require increased concentration and speed of psychomotor reactions.